GENFIT-ADR (GNFT) Stock Fundamental Analysis
USA - NASDAQ:GNFT - US3722791098 - ADR
4.2 USD
-0.04 (-0.85%)
4.4466 USD
+0.25 (+5.87%)
Overall GNFT gets a fundamental rating of 2 out of 10. We evaluated GNFT against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of GNFT have multiple concerns. GNFT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
GNFT had negative earnings in the past year.
GNFT had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GNFT reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of GNFT (-17.89%) is better than 79.03% of its industry peers.
GNFT has a Return On Equity (-73.87%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| ROIC | N/A |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GNFT's Profit Margin has declined in the last couple of years.
In the last couple of years the Operating Margin of GNFT has declined.
Looking at the Gross Margin, with a value of 95.42%, GNFT belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for GNFT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% |
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GNFT has been increased compared to 1 year ago.
The number of shares outstanding for GNFT has been increased compared to 5 years ago.
The debt/assets ratio for GNFT is higher compared to a year ago.
2.2 Solvency
GNFT has an Altman-Z score of -1.50. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT has a Altman-Z score (-1.50) which is in line with its industry peers.
A Debt/Equity ratio of 0.09 indicates that GNFT is not too dependend on debt financing.
The Debt to Equity ratio of GNFT (0.09) is worse than 63.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.5 |
ROIC/WACCN/A
WACC7.18%
2.3 Liquidity
GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
GNFT has a Current ratio (3.74) which is in line with its industry peers.
GNFT has a Quick Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.74, GNFT perfoms like the industry average, outperforming 45.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
The earnings per share for GNFT have decreased strongly by -327.32% in the last year.
GNFT shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -70.77% yearly.
GNFT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -45.94%.
Measured over the past years, GNFT shows a quite strong growth in Revenue. The Revenue has been growing by 11.61% on average per year.
EPS 1Y (TTM)-327.32%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-139.82%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-39.51%
3.2 Future
GNFT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.26% yearly.
Based on estimates for the next years, GNFT will show a decrease in Revenue. The Revenue will decrease by -2.23% on average per year.
EPS Next Y15.82%
EPS Next 2Y-94%
EPS Next 3Y-41.45%
EPS Next 5Y-29.26%
Revenue Next Year-8.28%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-2.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
GNFT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GNFT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as GNFT's earnings are expected to decrease with -41.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-94%
EPS Next 3Y-41.45%
5. Dividend
5.1 Amount
No dividends for GNFT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.2
-0.04 (-0.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.76%
Inst Owner Change0%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap210.01M
Revenue(TTM)45.41M
Net Income(TTM)-38760000
Analysts90.77
Price Target10.12 (140.95%)
Short Float %0.05%
Short Ratio3.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.25%
PT rev (3m)-4.79%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)717.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.18%
Revenue NY rev (3m)-11.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.97 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.44 | ||
| P/tB | 84.86 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS1.06
BVpS1.22
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% | ||
| FCFM | N/A |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 188.46% | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z | -1.5 |
F-Score2
WACC7.18%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-327.32%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-139.82%
EPS Next Y15.82%
EPS Next 2Y-94%
EPS Next 3Y-41.45%
EPS Next 5Y-29.26%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-39.51%
Revenue Next Year-8.28%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-2.23%
EBIT growth 1Y-216.85%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year-6.17%
EBIT Next 3Y-0.9%
EBIT Next 5YN/A
FCF growth 1Y87.25%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.33%
OCF growth 3Y-46.21%
OCF growth 5YN/A
GENFIT-ADR / GNFT FAQ
What is the fundamental rating for GNFT stock?
ChartMill assigns a fundamental rating of 2 / 10 to GNFT.
Can you provide the valuation status for GENFIT-ADR?
ChartMill assigns a valuation rating of 0 / 10 to GENFIT-ADR (GNFT). This can be considered as Overvalued.
Can you provide the profitability details for GENFIT-ADR?
GENFIT-ADR (GNFT) has a profitability rating of 2 / 10.
Can you provide the financial health for GNFT stock?
The financial health rating of GENFIT-ADR (GNFT) is 3 / 10.